{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T01:16:39Z","timestamp":1784337399441,"version":"3.55.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005057","name":"National Tsing Hua University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005057","name":"National Tsing Hua University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Glycan-masking the vaccine antigen by mutating the undesired antigenic sites with an additional\n                    <jats:italic>N<\/jats:italic>\n                    -linked glycosylation motif can refocus B-cell responses to desired epitopes, without affecting the antigen\u2019s overall-folded structure. This study examined the impact of glycan-masking mutants of the N-terminal domain (NTD) and receptor-binding domain (RBD) of SARS-CoV-2, and found that the antigenic design of the S protein increases the neutralizing antibody titers against the Wuhan-Hu-1 ancestral strain and the recently emerged SARS-CoV-2 variants Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2). Our results demonstrated that the use of glycan-masking Ad-S-R158N\/Y160T in the NTD elicited a 2.8-fold, 6.5-fold, and 4.6-fold increase in the IC-50 NT titer against the Alpha (B.1.1.7), Beta (B.1.351) and Delta (B.1.617.2) variants, respectively. Glycan-masking of Ad-S-D428N in the RBD resulted in a 3.0-fold and 2.0-fold increase in the IC-50 neutralization titer against the Alpha (B.1.1.7) and Beta (B.1.351) variants, respectively. The use of glycan-masking in Ad-S-R158N\/Y160T and Ad-S-D428N antigen design may help develop universal COVID-19 vaccines against current and future emerging SARS-CoV-2 variants.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2021.795741","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T04:49:12Z","timestamp":1638420552000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants"],"prefix":"10.3389","volume":"12","author":[{"given":"Wei-Shuo","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chien","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suh-Chin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"eabg0821","DOI":"10.1126\/science.abg0821","article-title":"SARS-CoV-2 Within-Host Diversity and Transmission","volume":"372","author":"Lythgoe","year":"2021","journal-title":"Science"},{"key":"B2","unstructured":"ViralZone SARS-CoV-2 Circulating Variants"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1126\/science.abg7404","article-title":"Immunity to SARS-CoV-2 Variants of Concern","volume":"371","author":"Altmann","year":"2021","journal-title":"Science"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1126\/science.abh2315","article-title":"Defining Variant-Resistant Epitopes Targeted by SARS-CoV-2 Antibodies: A Global Consortium Study","volume":"374","author":"Hastie","year":"2021","journal-title":"Science"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/j.cell.2021.03.028","article-title":"N-Terminal Domain Antigenic Mapping Reveals a Site of Vulnerability for SARS-CoV-2","volume":"184","author":"McCallum","year":"2021","journal-title":"Cell"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03944-y","article-title":"SARS-CoV-2 B.1.617.2 Delta Variant Replication and Immune Evasion","volume":"599","author":"Mlcochova","year":"2021","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.cell.2021.01.037","article-title":"Circulating SARS-CoV-2 Spike N439K Variants Maintain Fitness While Evading Antibody-Mediated Immunity","volume":"184","author":"Thomson","year":"2021","journal-title":"Cell"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/science.abh1139","article-title":"Structural and Functional Ramifications of Antigenic Drift in Recent SARS-CoV-2 Variants","volume":"373","author":"Yuan","year":"2021","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03324-6","article-title":"mRNA Vaccine-Elicited Antibodies to SARS-CoV-2 and Circulating Variants","volume":"592","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01294-w","article-title":"Resistance of SARS-CoV-2 Variants to Neutralization by Monoclonal and Serum-Derived Polyclonal Antibodies","volume":"27","author":"Chen","year":"2021","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03412-7","article-title":"Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA Vaccine-Elicited Antibodies","volume":"593","author":"Collier","year":"2021","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2102017","article-title":"Neutralizing Activity of BNT162b2-Elicited Serum","volume":"384","author":"Liu","year":"2021","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01285-x","article-title":"SARS-CoV-2 501y.V2 Escapes Neutralization by South African COVID-19 Donor Plasma","volume":"27","author":"Wibmer","year":"2021","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102214","article-title":"Efficacy of the ChAdOx1 Ncov-19 Covid-19 Vaccine Against the B.1.351 Variant","volume":"384","author":"Madhi","year":"2021","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e1000571","DOI":"10.1371\/journal.pbio.1000571","article-title":"How can Vaccines Against Influenza and Other Viral Diseases be Made More Effective","volume":"8","author":"Nara","year":"2010","journal-title":"PloS Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nri2801","article-title":"Structure-Function Relationships of HIV-1 Envelope Sequence-Variable Regions Refocus Vaccine Design","volume":"10","author":"Zolla-Pazner","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1357-4310(96)20036-X","article-title":"Can Epitope-Focused Vaccines Select Advantageous Immune Responses","volume":"3","author":"Delves","year":"1997","journal-title":"Mol Med Today"},{"key":"B19","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.159.1.279","article-title":"Refocusing Neutralizing Antibody Response by Targeted Dampening of an Immunodominant Epitope","volume":"159","author":"Garrity","year":"1997","journal-title":"J Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.2001.01242.x","article-title":"Refocusing of B-Cell Respones Following a Single Amino Acid Substitution in an Antigen","volume":"103","author":"Chiesa","year":"2001","journal-title":"Immunology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.10.5889-5901.2003","article-title":"Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric Gp120 as Novel Antigens for HIV Vaccine Design","volume":"77","author":"Pantophlet","year":"2003","journal-title":"J Virol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.19.12148-12163.2005","article-title":"Comparing Antigenicity and Immunogenicity of Engineered Gp120","volume":"79","author":"Selvarajah","year":"2005","journal-title":"J Virol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.immuni.2018.07.005","article-title":"Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies","volume":"49","author":"Duan","year":"2018","journal-title":"Immunity"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.09.080","article-title":"Deceptive Imprinting and Immune Refocusing in Vaccine Design","volume":"26","author":"Tobin","year":"2008","journal-title":"Vaccine"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e39075","DOI":"10.1371\/journal.pone.0039075","article-title":"Broader Neutralizing Antibodies Against H5N1 Viruses Using Prime-Boost Immunization of Hyperglycosylated Hemagglutinin DNA and Virus-Like Particles","volume":"7","author":"Lin","year":"2012","journal-title":"PloS One"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e92822","DOI":"10.1371\/journal.pone.0092822","article-title":"Glycan Masking of Hemagglutinin for Adenovirus Vector and Recombinant Protein Immunizations Elicits Broadly Neutralizing Antibodies Against H5N1 Avian Influenza Viruses","volume":"9","author":"Lin","year":"2014","journal-title":"PloS One"},{"key":"B27","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/bit.26810","article-title":"Glycan-Masking Hemagglutinin Antigens From Stable CHO Cell Clones for H5N1 Avian Influenza Vaccine Development","volume":"116","author":"Chen","year":"2019","journal-title":"Biotechnol Bioeng"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.7150\/thno.35919","article-title":"Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization","volume":"9","author":"Lin","year":"2019","journal-title":"Theranostics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"13473","DOI":"10.1038\/ncomms13473","article-title":"Introduction of Neutralizing Immunogenicity Index to the Rational Design of MERS Coronavirus Subunit Vaccines","volume":"7","author":"Du","year":"2016","journal-title":"Nat Commun"},{"key":"B30","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM Structure of the 2019-Ncov Spike in the Prefusion Conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"B32","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.cell.2020.09.018","article-title":"Molecular Architecture of the SARS-CoV-2 Virus","volume":"183","author":"Yao","year":"2020","journal-title":"Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb9983","article-title":"Site-Specific Glycan Analysis of the SARS-CoV-2 Spike","volume":"369","author":"Watanabe","year":"2020","journal-title":"Science"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6952","article-title":"A Neutralizing Human Antibody Binds to the N-Terminal Domain of the Spike Protein of SARS-CoV-2","volume":"369","author":"Chi","year":"2020","journal-title":"Science"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1016\/j.cell.2021.03.029","article-title":"Neutralizing and Protective Human Monoclonal Antibodies Recognizing the N-Terminal Domain of the SARS-CoV-2 Spike Protein","volume":"184","author":"Suryadevara","year":"2021","journal-title":"Cell"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd4251","article-title":"Distinct Conformational States of SARS-CoV-2 Spike Protein","volume":"369","author":"Cai","year":"2020","journal-title":"Science"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e2100943118","DOI":"10.1073\/pnas.2100943118","article-title":"Distant Residues Modulate Conformational Opening in SARS-CoV-2 Spike Protein","volume":"118","author":"Ray","year":"2021","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03925-1","article-title":"Lectins Enhance SARS-CoV-2 Infection and Influence Neutralizing Antibodies","volume":"598","author":"Lempp","year":"2021","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1101\/2020.11.05.369264","article-title":"The N-Terminal Domain of Spike Glycoprotein Mediates SARS-CoV-2 Infection by Associating With L-SIGN and DC-SIGN","author":"Soh","year":"2020","journal-title":"bioRxiv"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.0c01537","article-title":"CD209L\/L-SIGN and CD209\/DC-SIGN Act as Receptors for SARS-CoV-2","volume":"7","author":"Amraei","year":"2021","journal-title":"ACS Cent Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.795741\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T17:42:03Z","timestamp":1673890923000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.795741\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,2]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2021.795741"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.795741","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.11.01.466834","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,2]]},"article-number":"795741"}}